aramadourian_flagshippioneering
18 July 2018

LSIPR 50 2018: The entrepreneurial bug

Since its founding in 2000, Flagship Pioneering has set up and fostered the development of more than 100 scientific ventures, resulting in $20 billion in aggregate value, more than 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.

It’s a business that creates and manages life sciences ventures. Every year, it spins out six to eight new companies from its VentureLabs core (its innovation foundry), all of which have unique needs.

Among its impressive portfolio sits Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases, and genome-editing company Editas Medicine.

Aram Adourian, partner, knowledge management at Flagship Pioneering, explains: “In short, there are many ideas and interesting projects to pursue—which is a good problem to have!”

Adourian’s job is to lead a functional area that coordinates, supervises, and resources activities related to Flagship Pioneering’s internal scientific information requirements.

The aim is to leverage internal and external knowledge and informatics across the breadth of the company’s pioneering activities.

This ranges from bioinformatics and statistical and data analysis, to management and organisation of internally-generated knowledge, to mining external scientific and clinical information.

He’s constantly partnering across the organisation and ecosystem to work on the most pressing and mission-critical projects.

Multi-strand research

At 70 people and growing, Cambridge, Massachusetts-based Flagship Pioneering is an organisation “full of incredibly intelligent, motivated, and highly visionary people”, he says. And because of the unique process for innovation that the firm has honed over nearly two decades, it’s simultaneously exploring many interesting areas of science.

Flagship Pioneering builds first-in-category companies that create science-based innovations in health, nutrition, and sustainability. The primary focus is on the patients and populations for whom the investment company can improve life and health.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More on this story

Big Pharma
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More on this story

Big Pharma
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.